Robert Hindes, MD, serves as the chief medical officer at BeyondWest Pharmaceuticals. Currently, the company is planning clinical trials of treatments for hepatitis C in various countries in the developing world, with a particular focus on the Middle East and Latin America. Robert Hindes, MD, completed his infectious disease fellowship at Harvard Medical School, and his residency in internal medicine at the Medical College of Pennsylvania.
At present, the World Health Organization lists hepatitis C as a global pandemic, and considers the disease to be one of the chief public health concerns in developing nations. More than 170 million individuals suffer from the disease worldwide. Nearly 400,000 people die from hepatitis C every year, even as researchers develop effective treatments and continue to work on creating a vaccine.
Despite the expected approval of a number of highly effective drugs over the next couple of years, access to this treatment is not available to the majority of infected individuals in developing nations.
At present, the World Health Organization lists hepatitis C as a global pandemic, and considers the disease to be one of the chief public health concerns in developing nations. More than 170 million individuals suffer from the disease worldwide. Nearly 400,000 people die from hepatitis C every year, even as researchers develop effective treatments and continue to work on creating a vaccine.
Despite the expected approval of a number of highly effective drugs over the next couple of years, access to this treatment is not available to the majority of infected individuals in developing nations.